178421-22-2

Basic information

• Product Name: Methyl 6-chloro-5-Methylpicolinate
• Synonyms: Methyl 6-chloro-5-Methylpicolinate
• CAS NO: 178421-22-2
• Molecular Formula: C8H8ClNO2
• Molecular Weight: 185.60762
• Mol File: 178421-22-2.mol

Chemical Properties

• Boiling Point: 298.13 °C at 760 mmHg
• Flash Point: 134.104 °C
• Appearance: /
• Density: 1.248 g/cm³
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: -0.74±0.10(Predicted)
• CAS DataBase Reference: Methyl 6-chloro-5-Methylpicolinate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 6-chloro-5-Methylpicolinate(178421-22-2)
• EPA Substance Registry System: Methyl 6-chloro-5-Methylpicolinate(178421-22-2)

Safety Data

• Hazardous Substances Data: 178421-22-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 6-chloro-5-methylpicolinate is used as an intermediate in the synthesis of various pharmaceuticals for its potential role in the development of new drugs.
Used in Agrochemical Industry:
Methyl 6-chloro-5-methylpicolinate is used as a building block in the creation of agrochemicals, contributing to the development of effective and safe products for agricultural applications.
Used in Organic Compounds Synthesis:
Methyl 6-chloro-5-methylpicolinate is used as a key component in the synthesis of various organic compounds, facilitating the production of a wide range of chemical products.
Used in Chemical Research and Synthesis:
Methyl 6-chloro-5-methylpicolinate is utilized in chemical research and synthesis to explore its properties, reactions, and potential applications in various chemical processes.
It is important to handle and use Methyl 6-chloro-5-methylpicolinate with appropriate safety precautions, as it may be hazardous if not handled properly.

Upstream product

• 401792-77-6 methyl 5-methyl-2-pyridinecarboxylate N-oxide 
• 589-93-5 2,5-dimethylpyridine 
• 29681-38-7 methyl 5-methylpyridine-2-carboxylate 
• 67-56-1 methanol 
• 125849-97-0 4,6-dichloro-1-methyl-2-oxa-5-azabicyclo<2.2.2>oct-5-en-3-one 

Relevant articles and documents

3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS

The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.

PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME

Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11β-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11β-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human- derived 11β-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LAD A), insulin tolerance syndromes, obesity, impaired glucose tolerane (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.

2,4-DIAMINO-PYRIMIDINE DERIVATIVES

The invention concerns compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, Q, R3, and R4 are as defined in the description. The present invention also relates to processes for the preparation ofsuch compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4 kinases.

CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190

DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro- drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein, for example, Ring A is optionally substituted 2,6-pyrazindiyl; X is =O; Ring B is optionally substituted 1,4-phenylene; Y1 is a direct bond or -O-; Y2 is -(CH 2) r- wherein r is 2 or 3; n is 0 or n is 1 when Y1 is a direct bond between Ring B and Ring C and when Ring B is 1,4-phenylene and Ring C is (4-6C)cycloalkane; Ring C is optionally substituted (4-6C)cycloalkane, (7-10C)bicycloalkane, (8-12C)tricycloalkane, phenylene or pryidindiyl; L is a direct bond or -O-; p is 0, 1 or 2 and when p is 1 or 2 RA1 and RA2 are each independently hydrogen or (1-4C)alkyl; Z is carboxy or a mimic or bioisostere thereof.

A new pathway to substituted 6-chloro-2-pyridinecarboxylic acid derivatives from the reaction of 4,6-dichloro-2-oxa-5-azabicyclo[2.2.2]oct-5-en-3-ones with nucleophiles

Reaction of alcohols or amines with 4,6-dichloro-2-oxa-5-azabicyclo[2.2.2]oct-5-en-3-ones gives direct conversion into (3,(4,))5-substituted 6-chloro-2-pyridinecarboxylic acid derivatives via selective lactone cleavage followed by rapid elimination of HCl and H2O in the presence of DBU. Copyright